Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Celebrations may be in order for Alpine Immune Sciences, Inc. (NASDAQ:ALPN) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have sharply increased their revenue numbers, with a view that Alpine Immune Sciences will make substantially more sales than they'd previously expected.

After the upgrade, the six analysts covering Alpine Immune Sciences are now predicting revenues of US$42m in 2021. If met, this would reflect a sizeable 132% improvement in sales compared to the last 12 months. Losses are presumed to reduce, shrinking 14% from last year to US$1.26. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$29m and losses of US$1.31 per share in 2021. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

See our latest analysis for Alpine Immune Sciences

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Alpine Immune Sciences' rate of growth is expected to accelerate meaningfully, with the forecast 4x annualised revenue growth to the end of 2021 noticeably faster than its historical growth of 108% p.a. over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 10.0% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Alpine Immune Sciences is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Alpine Immune Sciences' prospects. They also upgraded their revenue estimates for this year, and sales are expected to grow faster than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Alpine Immune Sciences.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Alpine Immune Sciences analysts - going out to 2023, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

If you’re looking to trade Alpine Immune Sciences, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.